MRNA

ModernaC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$58.00

+16.8% vs current

Most likely

Base case

45%

Probability

Target price

$43.00

-13.4% vs current

B-

Bear case

25%

Probability

Target price

$30.00

-39.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

Tone improved after the May 1, 2026 earnings release because revenue beat expectations and trusted coverage linked the move to stronger international COVID sales, with reports of a positive same-day share reaction. But this is a T+3 monitoring setup, not a clean thesis upgrade: the anchor price of $45.37 still sits above the packet's median analyst target, visible analyst revision flow remains sparse or mixed, and the market still needs proof that the beat reflects more than partnership timing and that the 2026 pipeline calendar can support the cash-runway story.

RankAlpha Sentiment Codex - 2026-05-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystPost-earnings estimate digestion after Q1 revenue beatMedium impact

Q1 2026 revenue was $389 million, with roughly 80% from international markets, while management reiterated its 2026 plan for up to 10% revenue growth and operating-expense reduction excluding the litigation charge; the near-term question is whether investors and analysts treat the beat as durable demand improvement or largely timing/partnership-driven [#8-K-2026-05-01].

2026-08-05eventAugust 5, 2026 FDA decision date for mRNA-1010 seasonal flu vaccineHigh impact

Moderna said the FDA assigned a PDUFA goal date of August 5, 2026 for mRNA-1010. Approval would add a fifth approved product and help validate the broader respiratory platform; delay or rejection would reinforce skepticism around the non-COVID revenue bridge [#8-K-2026-05-01].

2026-11-15catalyst2026 late-stage pipeline readouts need to offset cash-burn concernsHigh impact

Management highlighted potential 2026 milestones for norovirus Phase 3, adjuvant melanoma Phase 3, and propionic acidemia registrational data, while also guiding year-end 2026 cash and investments to $4.5-$5.0 billion and a $950 million settlement payment in Q3 2026; positive readouts and disciplined cash execution are needed to sustain a rerating [#8-K-2026-05-01].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology